10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ELOVL2 Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP13461b

Specification

ELOVL2 Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q9NXB9

ELOVL2 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 54898

Other Names
Elongation of very long chain fatty acids protein 2, 3-keto acyl-CoA synthase ELOVL2, ELOVL fatty acid elongase 2, ELOVL FA elongase 2, Very-long-chain 3-oxoacyl-CoA synthase 2, ELOVL2, SSC2

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13461b was selected from the C-term region of ELOVL2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ELOVL2 Antibody (C-term) Blocking peptide - Protein Information

Name ELOVL2 {ECO:0000255|HAMAP-Rule:MF_03202}

Function
Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that catalyzes the synthesis of polyunsaturated very long chain fatty acid (C20- and C22-PUFA), acting specifically toward polyunsaturated acyl-CoA with the higher activity toward C20:4(n-6) acyl-CoA. May participate in the production of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.

Cellular Location
Endoplasmic reticulum membrane {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000269|PubMed:20937905}; Multi- pass membrane protein

{ECO:0000255|HAMAP-Rule:MF_03202}

Tissue Location
Liver and testis..

ELOVL2 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

ELOVL2 Antibody (C-term) Blocking peptide - Images

ELOVL2 Antibody (C-term) Blocking peptide - Background

ELOVL2 could be implicated in tissue-specific synthesis of very long chain fatty acids and sphingolipids. May catalyze one or both of the reduction reaction in fatty acid elongation, i.e., conversion of beta-ketoacyl CoA to beta-hydroxyacyl CoA or reduction of trans-2-enoyl CoA to the saturated acyl CoA derivative (By similarity).

ELOVL2 Antibody (C-term) Blocking peptide - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Illig, T., et al. Nat. Genet. 42(2):137-141(2010)Tanaka, T., et al. PLoS Genet. 5 (1), E1000338 (2009) :Lu, Y., et al. J. Lipid Res. 49(12):2582-2589(2008)Kobayashi, T., et al. FEBS Lett. 581(17):3157-3163(2007)